Governance Classic Home
Akums Drugs and Pharmaceuticals LtdPharmaceuticalsINE09XN01023Consolidated₹750.55-9.45 (-1.24%)
Valuation
Market Cap₹11.83K Cr
TTM PE31.63x
Forward PE29.01x
PEG1.28
Book Value₹222.55
P/B3.38x
TTM EPS₹23.76
Fwd EPS₹25.91
TTM Revenue₹4.83K Cr
TTM PAT₹364.56 Cr
TTM EBITDA₹668.00 Cr
TTM EBIT₹503.95 Cr
Last Qtr PAT₹114.57 Cr
Last Qtr EBITDA₹194.73 Cr
Last Qtr EBIT₹151.52 Cr
Profitability
ROE10.41%
ROCE16.93%
TTM NPM7.55%
TTM EBITDA %13.84%
Curr OPM8.35%
Last OPM8.44%
Curr NPM—
Last NPM—
Curr EPS₹7.37
Last EPS₹6.53
Balance sheet
Equity₹30.62 Cr
Reserve₹3.47K Cr
Total Debt₹117.06 Cr
D/E0.03x
Interest %22.41%
Curr Interest₹25.68 Cr
Price / range
Close₹751.50
vs 52W High—
vs 52W Low—
MA50—
MA200—
Returns
1D-1.27%
1W+3.21%
1M-7.74%
3M+12.45%
6M+34.21%
1Y+59.59%
2Y-11.10%
3Y—
5Y—
Diwali+68.31%
Sector peers — Pharmaceuticals
CompanyCloseMkt CapTTM P/EROE
SUNPHARMA1773.40₹4.25L Cr38.8112.31%
DIVISLAB10037.50₹2.66L Cr91.0817.45%
TORNTPHARM4738.50₹1.60L Cr77.7711.42%
LAURUSLABS2323.80₹1.25L Cr93.6321.98%
ZYDUSLIFE1188.10₹1.20L Cr28.5315.79%
DRREDDY1374.00₹1.15L Cr40.897.11%
CIPLA1402.00₹1.13L Cr39.098.06%
MANKIND2537.90₹1.05L Cr46.7112.87%

Financial Results

Quarterly and yearly P&L · YoY % on Revenue, Total Income, Expenditure, EBITDA, EBIT, PBT, Net Profit and EPS

Standalone

16 lines · 6 periods
MetricSep-26Jun-26Mar-26Dec-25Sep-25FY25-26
Revenue395.05+27.7%392.28338.37368.61309.321,348.74
Other Income25.8026.1027.7329.6027.08112.97
Total Income420.84+25.1%418.38366.10398.21336.391,461.70
Interest32.482.592.462.0810.04
Expenditure-377-23.5%-359.04-341.60-358.54-305.19-1,306.82
PBDT000000
EBITDA34.56+104.5%48.5211.7824.6816.9097.46
Depreciation-13.51-12.80-12.42-12.15-10.69-45.50
EBIT21.05+239.0%35.72-0.6412.536.2151.96
PBT43.85+40.5%59.3421.7935.8731.20148.37
Tax-11.21-14.50-6.59-7.75-7.74-36.73
Equity30.6230.6230.6230.62030.62
OPM10.4214.185.959.0110.0910.15
Net Profit32.64+39.1%44.8415.2028.1123.46111.64
NPM7.7610.724.157.067.597.64
EPS2.13+39.2%2.930.991.841.537.29

Yearly results

Last 6 financial years · YoY % vs previous FY

Yearly

17 lines · 2 years
MetricFY 25-26FY 24-25
Revenue1,348.74+2.8%1,311.78
Other Income112.97124.19
Total Income1,461.70+1.8%1,435.98
Expenditure-1,306.82-6.4%-1,228.14
Interest-10.04-15.31
PBDT00
EBITDA97.46-29.6%138.50
Depreciation-45.50-39.55
EBIT51.96-47.5%98.95
PBT148.37-28.6%207.84
Tax-36.73-46.84
Equity30.6230.62
OPM (%)10.1514.47
Net Profit111.64-30.7%161
NPM (%)7.6411.21
EPS (Rs)7.29-32.2%10.76
CEPS7.2910.76

Consolidated

16 lines · 6 periods
MetricSep-26Jun-26Mar-26Dec-25Sep-25FY25-26
Revenue1,342.39+31.9%1,166.631,157.871,159.591,017.534,359.02
Other Income28.9130.3835.3034.3332.37128.73
Total Income1,371.29+30.6%1,197.011,193.171,193.921,049.904,487.74
Interest25.6824.7623.8923.7423.3094.07
Expenditure-1,216.55-23.6%-1,057.77-1,070.16-1,076.12-984.22-4,085.62
PBDT000000
EBITDA194.73+106.1%174.69151.72146.8694.47522.02
Depreciation-43.21-41.07-40.12-39.65-37.86-154.55
EBIT151.52+167.7%133.62111.60107.2156.61367.47
PBT154.74+135.6%139.24121.2299.5765.67382.10
Tax-40.18-38.26-39.87-31.89-22.98-125.70
Equity30.6230.6230.620030.62
OPM11.2811.6310.168.346.268.51
Net Profit114.57+168.3%100.9881.3467.6742.70256.40
NPM8.358.446.825.674.075.71
EPS7.37+177.1%6.535.534.332.6616.67

Yearly results

Last 6 financial years · YoY % vs previous FY

Yearly

17 lines · 2 years
MetricFY 25-26FY 24-25
Revenue4,359.02+5.8%4,118.16
Other Income128.7352.12
Total Income4,487.74+7.6%4,170.28
Expenditure-4,085.62-6.3%-3,841.72
Interest-94.07-34.60
PBDT00
EBITDA522.02+12.4%464.49
Depreciation-154.55-153.45
EBIT367.47+18.1%311.04
PBT382.10+10.7%345.25
Tax-125.70-1.48
Equity30.6230.62
OPM (%)8.518.28
Net Profit256.40-25.4%343.78
NPM (%)5.718.24
EPS (Rs)16.67-26.2%22.60
CEPS16.6722.60

Corporate Actions

Dividends, bonus issues, and stock splits

Dividend

2
YearTypeAmountEx-Date
2026Final Dividend103 Jul 2026
2026Special Dividend203 Jul 2026

Bonus

0

No bonus history.

Split

0

No split history.

Loading company dashboard...
Fetching ratios, charts, and peers